Over-the-counter drug · BLA
Novolin 70/30 (Human insulin) NDC 50090-0403
Insulin human 100 [iU]/mL · Injection, Suspension · Subcutaneous · A-S Medication Solutions
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50090-0403-0 | 5009004030050090040300 | 1 VIAL in 1 CARTON (50090-0403-0) / 10 mL in 1 VIALMarketed from Nov 28, 2014 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Novolin 70/30Suffix: 70/30
- Generic name (nonproprietary)
- human insulin
- Active ingredients
- Insulin human — 100 [iU]/mL
- Dosage form
- Injection, Suspension
- Route
- Subcutaneous
- Labeler
- A-S Medication SolutionsNDC labeler code 50090
- Product type
- Over-the-counter drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 019991
- Marketing start
- Listing expires
- Other FDA classes
- Insulin (Chemical structure)
- Identifiers
- Product ID 50090-0403_6ffa1a5f-1a62-4017-999c-8ef13fa4f0c7SPL ID 6ffa1a5f-1a62-4017-999c-8ef13fa4f0c7SPL set ID e825d7e9-467c-4f50-a6d6-f2602449c1deRxCUI 213442, 311048UNII 1Y17CTI5SR
- Pharmacologic class
- Insulin
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N450090040300followed by a unit qualifier and the quantityPackage 50090-0403-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
NOVOLIN 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. Limitations of Use: In NOVOLIN 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. NOVOLIN 70/30 is a mixture of human insulin isophane, an intermediate-acting human insulin, and human insulin, a short-acting human insulin, indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 50090-0403
- What is NDC 50090-0403?
- 50090-0403 is the product NDC for Novolin 70/30 (human insulin), Insulin human 100 [iU]/mL injection, suspension, listed with the FDA by A-S Medication Solutions. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Novolin 70/30 (Human Insulin).
- What is the active ingredient?
- Insulin human.
- Who is the labeler?
- A-S Medication Solutions, NDC labeler code 50090. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Novolin 70/30?
- 2 other product NDCs are listed under this name. See all Novolin 70/30 NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Novolin 70/30 products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Novolin 70/30human insulin | Insulin human 100 [iU]/mL | Injection, SuspensionSubcutaneous | Novo Nordisk Pharmaceutical Industries, LP | 0169-3007 | 00169-3007-1500169-3007-25 |
| Novolin 70/30human insulin | Insulin human 100 [iU]/mL | Injection, SuspensionSubcutaneous | Novo Nordisk Pharmaceutical Industries, LP | 0169-1837 | 00169-1837-0200169-1837-11 |
Other NDCs under BLA 019991
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Novolin 70/30human insulin | Insulin human 100 [iU]/mL | Injection, SuspensionSubcutaneous | Novo Nordisk Pharmaceutical Industries, LP | 0169-1837 |
| Novolin 70/30human insulin | Insulin human 100 [iU]/mL | Injection, SuspensionSubcutaneous | Novo Nordisk Pharmaceutical Industries, LP | 0169-3007 |